Multinational pharmaceuticals surprised by Novartis crisis, “Lawful academic supports should not be restricted”

As the prosecution’s Novartis rebate investigation which was conducted from last February was finalized with indictment of 34 people including its current and former executives without detention, other multinational pharmaceutical companies is sparing themselves to avoid issues related to the crisis.

Along with the enforcement of the Kim Young-ran Law scheduled on the 28^th of September, the en...